Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), Prana Biotechnology Limited (NASDAQ: PRAN), and Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. BioMarin Pharmaceutical Inc. Research Report On November 15, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that the French National Agency for Medicines and Health Products Safety has granted an Autorisation Temporaire d'Utilisation de cohorte, or Temporary Authorization for Use, for patient sales of Vimizim for the treatment of Morquio A Syndrome. According to BioMarin, the ATU allows patients with Morquio A Syndrome in France to receive treatment with Vimizim before marketing authorization for the product is granted in the European Union. Jeff Ajer, Senior Vice President, Global Commercial Operations at BioMarin, stated, "We look forward to working closely with European regulatory authorities through the final stages of full market approval in this region." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN -- Vanda Pharmaceuticals, Inc. Research Report On November 14, 2013, Vanda Pharmaceuticals, Inc. (Vanda) announced that the US Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (Advisory Committee) voted overwhelmingly to recommend the approval of the New Drug Application (NDA) for tasimelteon, with proposed trade name HETLIOZ, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. Commenting on the recommendation, Mihael H. Polymeropoulos M.D., Vanda's President and CEO, said, "We are now one step closer toward our goal of providing a treatment option that addresses the physiologic cause of this serious, debilitating orphan condition that impacts a majority of totally blind individuals." The Full Research Report on Vanda Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/b5ad_VNDA -- Cadence Pharmaceuticals Inc. Research Report On November 14, 2013, Cadence Pharmaceuticals Inc. (Cadence) announced that the US District Court for the District of Delaware has ruled in favor of Cadence in relation to the Company's patent infringement lawsuit against Exela Pharma Sciences, LLC. Ted Schroeder, President and CEO of Cadence, commented, "We are very pleased with the Court's decision, as it confirms our belief in the strength and validity of the patents covering OFIRMEV." Schroeder added, "Our focus remains on continuing to drive OFIRMEV's strong performance. We continue to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013. We remain confident in our franchise, and look forward to updating investors further on our progress." The Full Research Report on Cadence Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/f5e5_CADX -- Prana Biotechnology Limited Research Report On November 15, 2013, Prana Biotechnology Limited (Prana) issued an official response regarding a news story which indirectly reference Prana's Phase II clinical drug trial of PBT2 for Alzheimer's disease, IMAGINE. Prana informed that it was neither aware of the segment and nor did it participate in the segment, and the Company, the clinical investigators, and the patients involved are unaware of the treatment assignment (PBT2 or a placebo). The Company further reported that the IMAGINE trial is a randomised, double-blind trial, whose results are expected to be released in March 2014. . Prana reported that it issued this official response under ASX Guidance Note 8 Continuous Disclosure to avoid any uncertainty and has not received a request from the ASX. The Company expects to release the results of IMAGINE in March 2014. The Full Research Report on Prana Biotechnology Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/9f3a_PRAN -- Biostar Pharmaceuticals, Inc. Research Report On November 14, 2013, Biostar Pharmaceuticals, Inc. (Biostar) released its Q3 2013 results. Biostar registered net sales of $15.0 million, up 50.1% YoY in Q3 2013. The Company posted comprehensive income of $1.7 million in Q3 2013, compared to comprehensive loss of $6.1 million in Q3 2012. Biostar reported diluted EPS of $0.03 in Q3 2013, compared to diluted loss per share of $0.63 in Q3 2012. Ronghua Wang, Chairman of Biostar, commented, "Thanks to the efforts of our entire team and the continued support shown in our market channel by both consumers and our suppliers, for the nine months ended September 30, 2013, the Company achieved sales revenue of $41.75 million, cash flow from operations of $13.71 million, and net profits of $0.22 million." The Full Research Report on Biostar Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/9687_BSPM ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence,
Press spacebar to pause and continue. Press esc to stop.